William Nye
Global gene therapy market valued at over $10 billion in 2023, projected to surpass $25 billion by 2028, underscoring the explosive growth and investment in genetic medicine, with CRISPR technology at its forefront.
CRISPRs Next Frontier: Gene Editing Cures and Ethical Quandaries
The revolutionary gene-editing technology, CRISPR-Cas9, once a niche tool in molecular biology labs, has rapidly ascended to become a beacon of hope for treating a myriad of diseases. Its precision and relative ease of use have propelled it to the forefront of biomedical innovation, promising cures for conditions previously deemed untreatable. However, this potent scientific advancement is not without its complexities. As CRISPR moves from the laboratory bench to the patient bedside, it brings with it profound ethical questions that society must grapple with, ranging from the potential for unintended consequences to the very definition of human enhancement.
From Lab Curiosity to Therapeutic Revolution
The journey of CRISPR from a bacterial defense mechanism to a cutting-edge gene-editing tool is a testament to scientific ingenuity. Discovered as an adaptive immune system in bacteria and archaea, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and its associated protein Cas9 were repurposed by scientists like Jennifer Doudna and Emmanuelle Charpentier into a versatile system for precisely editing DNA. This breakthrough, for which they were awarded the Nobel Prize in Chemistry in 2020, allows researchers to target specific genes, snip out faulty sequences, and replace them with correct ones. The implications are vast, opening doors to correcting genetic mutations responsible for inherited diseases.
Initial research focused on understanding the fundamental mechanisms of CRISPR. Scientists meticulously mapped its natural function in microbial immunity, observing how bacteria use it to store and then cut out viral DNA. This foundational knowledge was crucial for adapting the system for use in eukaryotic cells, including human ones. The development of guide RNA molecules, which direct the Cas9 enzyme to the precise location in the genome, was a pivotal step. This molecular choreography allows for unprecedented accuracy in gene editing, minimizing off-target effects and maximizing therapeutic potential.
Early applications of CRISPR were primarily in research settings, enabling scientists to create precise genetic models of diseases in cell cultures and animal models. This accelerated the understanding of disease pathogenesis and the testing of potential therapeutic strategies. The ability to easily introduce or correct specific mutations in these models proved invaluable, vastly speeding up the drug discovery and development pipeline for genetic disorders. It democratized genetic research, making sophisticated gene editing accessible to a wider range of laboratories.
The transition to therapeutic applications began with in vitro studies and then moved to ex vivo therapies, where cells are removed from a patient, edited in a lab, and then reinfused. This approach offers a controlled environment and a reduced risk of off-target edits directly within the body. For example, editing a patient's own blood stem cells to correct a genetic defect before transplanting them back into the patient. This has been a crucial stepping stone towards in vivo therapies, where gene editing occurs directly within the patient's body.
The Mechanism Unpacked
At its core, the CRISPR-Cas9 system functions like a molecular scissor. A 'guide RNA' molecule, designed by scientists, acts as a GPS, leading the Cas9 protein to a specific DNA sequence within the genome. Once at the target site, Cas9 makes a precise cut. This break in the DNA then triggers the cell's natural repair mechanisms. Researchers can leverage these repair pathways to either inactivate a faulty gene or insert a new, functional gene sequence. The programmability of the guide RNA is what makes CRISPR so powerful and versatile, allowing for targeting of virtually any gene.
The specificity of CRISPR is a key advantage. Unlike earlier gene-editing techniques that were less precise and prone to causing unwanted mutations, CRISPR-Cas9 can be programmed to target incredibly specific sequences. This precision is critical for therapeutic applications, where off-target edits could lead to unforeseen and potentially harmful side effects. While not entirely eliminating the risk, the accuracy of CRISPR is significantly higher, making it a more viable option for clinical use. Ongoing research continues to refine the system, developing variants of Cas proteins and delivery methods to further enhance specificity and efficiency.
The 'editing' part of CRISPR can manifest in several ways. The most common is the creation of a double-strand break, which the cell then repairs. This repair process can be manipulated to achieve desired outcomes. For instance, if the goal is to disable a gene, the cell's imperfect repair mechanism might introduce small insertions or deletions (indels) at the cut site, effectively disrupting the gene's function. Alternatively, if a correct DNA sequence needs to be inserted, a template DNA can be provided alongside the CRISPR components, which the cell can use to repair the break accurately.
Beyond Cas9: Evolving CRISPR Systems
While CRISPR-Cas9 remains the most widely known and utilized system, the field is constantly evolving with the discovery and engineering of new CRISPR-associated (Cas) proteins. Systems like CRISPR-Cas12, Cas13, and even smaller, more efficient Cas variants are being developed. These new systems offer different cutting mechanisms, target different nucleic acids (RNA in the case of Cas13), or possess altered enzymatic properties, expanding the toolkit available for gene editing and opening up new therapeutic avenues. For example, some newer Cas variants are 'nickases,' making only a single-strand cut, which can reduce off-target effects and allow for more precise gene modifications.
The development of base editing and prime editing represents further refinements of CRISPR technology. Base editing allows for single-letter changes in the DNA without creating double-strand breaks, offering a gentler and potentially safer approach for correcting specific point mutations. Prime editing is even more versatile, capable of making a wider range of edits, including insertions, deletions, and all 12 possible base-to-base conversions, all without double-strand breaks. These advanced techniques are crucial for tackling diseases caused by single-nucleotide polymorphisms (SNPs), which are responsible for a significant portion of genetic disorders.
The innovation extends to delivery methods as well. Researchers are exploring various ways to get the CRISPR machinery into target cells efficiently and safely. Viral vectors, such as adeno-associated viruses (AAVs), have been a common choice due to their ability to infect cells and deliver genetic material. However, concerns about immunogenicity and payload capacity have led to the development of non-viral methods, including lipid nanoparticles (LNPs), electroporation, and even direct injection of CRISPR-protein complexes. The choice of delivery method is critical and depends heavily on the target tissue and the specific gene edit being performed.
Targeting Disease at the Source: Promising Clinical Applications
The potential of CRISPR to cure genetic diseases is no longer theoretical. Several clinical trials are underway, showing promising results for conditions like sickle cell disease, beta-thalassemia, and certain types of cancer. By correcting the underlying genetic defect, these therapies aim for a one-time, permanent cure, offering a radical departure from traditional treatments that often manage symptoms rather than address the root cause.
Sickle cell disease, a debilitating inherited blood disorder, is one of the most prominent targets for CRISPR-based therapies. In this condition, a single mutation in the beta-globin gene leads to the production of abnormal hemoglobin, causing red blood cells to become rigid and sickle-shaped. This can lead to severe pain, organ damage, and a shortened lifespan. Early clinical trials for CRISPR-based treatments have shown remarkable success, with patients experiencing significant reductions in debilitating pain crises and becoming transfusion-independent.
Beta-thalassemia, another inherited blood disorder affecting hemoglobin production, is also seeing significant progress. Similar to sickle cell disease, it stems from mutations in the genes responsible for hemoglobin synthesis. CRISPR therapies are being developed to restore functional hemoglobin production, offering the potential to alleviate the need for lifelong blood transfusions and iron chelation therapy. The results from ongoing trials are highly encouraging, with many patients demonstrating sustained clinical improvement after treatment.
Beyond blood disorders, CRISPR is being investigated for a wide range of other genetic conditions. These include inherited forms of blindness, cystic fibrosis, Huntington's disease, and muscular dystrophy. For instance, in hereditary blindness, gene editing could be used to correct mutations in photoreceptor cells, potentially restoring vision. The challenge in these cases often lies in delivering the CRISPR components effectively to the affected tissues deep within the body.
Cancer immunotherapy is another area where CRISPR is making a significant impact. It is being used to engineer a patient's own immune cells, such as T-cells, to better recognize and attack cancer cells. By modifying genes within these immune cells, researchers can enhance their cancer-fighting capabilities, making them more potent and persistent. This has led to the development of 'designer' T-cell therapies that show promise against various blood cancers and solid tumors.
Ex Vivo Therapies: A Stepping Stone to Cures
The majority of current CRISPR therapeutic applications involve ex vivo editing. This approach is considered safer for initial clinical trials because the gene editing process occurs outside the patient's body. Hematopoietic stem cells, responsible for producing all blood and immune cells, are a prime target for ex vivo editing. These cells are harvested from the patient, treated with CRISPR in a laboratory to correct the genetic defect, and then reinfused into the patient. Because these are stem cells, they can regenerate the entire blood and immune system with the corrected genetic information.
For conditions like sickle cell disease and beta-thalassemia, ex vivo editing of hematopoietic stem cells has been a game-changer. The edited stem cells, when reintroduced into the patient, begin producing healthy red blood cells, effectively curing the disease. This method allows for precise control over the editing process and minimizes the risk of off-target edits occurring in unintended tissues within the body. It also enables the selection and expansion of successfully edited cells before reintroduction.
The process typically involves isolating CD34+ stem cells from the patient's bone marrow or peripheral blood. These cells are then incubated with the CRISPR-Cas9 system, often delivered via electroporation, which uses electrical pulses to temporarily create pores in the cell membrane, allowing the CRISPR components to enter. After the editing process, the cells are checked for successful edits and then infused back into the patient, often following a conditioning regimen of chemotherapy to make space for the newly introduced cells. This approach has demonstrated high efficacy in clinical trials, with many patients achieving sustained disease remission.
In Vivo Therapies: The Next Frontier
While ex vivo therapies are showing great promise, the ultimate goal for many genetic diseases is in vivo gene editing, where the CRISPR machinery is delivered directly into the patient's body to edit cells in their natural environment. This approach is particularly important for diseases affecting tissues that are difficult to access or remove, such as the brain, lungs, or muscles. However, in vivo delivery presents significant challenges, including ensuring efficient delivery to the correct cell types, controlling the editing process, and avoiding immune responses to the delivery vectors and CRISPR components.
One of the major hurdles for in vivo therapies is the delivery mechanism. Viral vectors, particularly AAVs, are being explored extensively for their ability to target specific organs and cell types. For example, AAVs can be engineered to target liver cells, which are responsible for producing many essential proteins. Researchers are also developing non-viral delivery systems, such as lipid nanoparticles (LNPs), which have shown success in delivering mRNA and are being adapted for CRISPR components. The development of safe and effective in vivo delivery systems is paramount to unlocking the full therapeutic potential of CRISPR.
Beyond genetic disorders, in vivo CRISPR editing is also being explored for infectious diseases. For instance, researchers are investigating its use to target and disable viral DNA integrated into host genomes, such as with HIV. Other potential applications include editing genes to confer resistance to certain pathogens or to modulate the immune system for therapeutic benefit. These applications highlight the broad and transformative potential of CRISPR beyond inherited conditions.
| Disease | Therapeutic Target | Stage of Trial | Key Outcome Metrics |
|---|---|---|---|
| Sickle Cell Disease | Ex vivo editing of hematopoietic stem cells (e.g., BCL11A gene) | Phase 1/2/3 | Reduction in vaso-occlusive crises, transfusion independence, sustained fetal hemoglobin levels |
| Beta-Thalassemia | Ex vivo editing of hematopoietic stem cells (e.g., BCL11A gene) | Phase 1/2/3 | Transfusion independence, normal hemoglobin levels, reduced iron overload |
| Hereditary Transthyretin Amyloidosis | In vivo editing of liver cells to reduce TTR protein production | Phase 1 | Reduction in serum TTR levels, improvement in neurological symptoms |
| Hereditary Blindness (e.g., Leber Congenital Amaurosis) | In vivo editing of retinal cells | Phase 1/2 | Improvement in visual acuity, light sensitivity, and visual field |
| Non-Small Cell Lung Cancer | Ex vivo editing of T-cells for CAR-T therapy | Phase 1 | Tumor response rates, progression-free survival |
The Double-Edged Sword: Unpacking the Ethical Imperatives
The immense power of CRISPR technology inevitably raises significant ethical questions. The ability to alter the human genome, especially in ways that could be passed down to future generations (germline editing), sparks debates about safety, consent, equity, and the very essence of what it means to be human. These are not merely academic discussions; they require careful consideration as the technology advances.
One of the most contentious issues is germline editing. Unlike somatic cell editing, which affects only the individual being treated, germline editing alters DNA in sperm, eggs, or embryos. These changes would be heritable, meaning they would be passed on to all subsequent generations. While this could potentially eradicate inherited diseases permanently, it also carries the risk of unintended, permanent alterations to the human gene pool. The scientific community largely agrees that germline editing for reproductive purposes is not yet safe or ethically justifiable, given the current limitations and potential for unforeseen consequences. The debate is further complicated by the potential for "enhancement" uses, where genes might be altered for non-therapeutic reasons, such as improving intelligence or athletic ability, raising concerns about designer babies and exacerbating societal inequalities.
Another critical ethical consideration is equitable access. CRISPR-based therapies are likely to be very expensive, at least in their early stages of development. This raises concerns about whether these life-saving treatments will be accessible to everyone who needs them, or if they will be limited to wealthy individuals and developed nations, further widening global health disparities. Ensuring affordability and broad accessibility will be a major challenge for healthcare systems and policymakers worldwide.
Safety and Unintended Consequences
Despite its precision, CRISPR is not infallible. Off-target edits, where the Cas9 enzyme cuts DNA at unintended locations in the genome, remain a significant concern. These unintended edits could potentially disrupt other genes, leading to new health problems, including cancer. While researchers are continuously working to improve the specificity of CRISPR systems and develop robust methods for detecting off-target edits, the risk cannot be entirely eliminated, especially in the context of complex biological systems within the human body.
Mosaicism, where not all cells in an organism are edited, is another challenge. This can occur if the CRISPR system is not delivered effectively to all target cells. The presence of both edited and unedited cells could lead to unpredictable therapeutic outcomes or even exacerbate the disease. Ensuring uniform editing across all relevant cells is crucial for achieving consistent and effective treatment. Furthermore, the long-term effects of CRISPR-induced genetic changes are largely unknown. Studies are ongoing to monitor patients in clinical trials for any late-onset adverse events.
The immune response to CRISPR components and delivery vectors is another safety aspect. The human body may recognize the Cas protein or the viral vectors used for delivery as foreign, triggering an immune reaction that could neutralize the therapy or cause harmful inflammation. Developing immune-tolerant delivery systems and understanding how to manage immune responses are critical for the success of in vivo CRISPR therapies. Pre-existing immunity to common viruses like AAVs can also limit their effectiveness in some individuals.
The Specter of Enhancement vs. Therapy
The line between treating disease and enhancing human capabilities is a blurry one, and CRISPR technology blurs it further. While the primary focus is on curing genetic disorders, the potential to use CRISPR to enhance traits like intelligence, physical strength, or even lifespan raises profound ethical dilemmas. This possibility leads to concerns about a future where access to such enhancements is dictated by socioeconomic status, creating a genetic divide and potentially exacerbating existing inequalities.
The concept of 'designer babies'—children whose traits have been selected or engineered before birth—is a prominent example of this concern. While parents may wish to give their children the best possible start in life, the ability to alter non-disease-related traits raises questions about parental rights, the autonomy of future individuals, and the societal implications of a gene-edited population. International guidelines and regulations are still being developed to address these complex issues, with many countries currently prohibiting germline editing for reproductive purposes.
Moreover, what constitutes a 'disease' versus a 'trait' can be subjective. For instance, is short stature a condition to be treated, or a natural human variation? The ability to alter genes could lead to societal pressure to conform to certain genetic ideals, potentially reducing human diversity and individuality. These discussions require broad societal input, involving scientists, ethicists, policymakers, and the public to establish ethical boundaries for the application of gene-editing technologies.
Navigating the Regulatory Labyrinth and Public Perception
The rapid pace of CRISPR development poses a significant challenge for regulatory bodies worldwide. Establishing clear, effective, and adaptable frameworks to oversee gene-editing technologies is crucial for ensuring safety, ethical compliance, and public trust. Different countries and regions are adopting varied approaches, leading to a complex global regulatory landscape.
In the United States, the Food and Drug Administration (FDA) oversees gene therapies, evaluating their safety and efficacy through rigorous clinical trials. The FDA has established pathways for approving novel gene therapies, and several CRISPR-based treatments are currently in advanced stages of clinical development and review. However, the regulatory process for gene editing is still evolving, particularly concerning the distinction between somatic and germline editing, and the potential for off-target effects. The National Institutes of Health (NIH) also plays a role in guiding research, particularly in areas like germline editing, which it has largely restricted from federal funding.
Europe has a similarly stringent regulatory environment, with the European Medicines Agency (EMA) responsible for evaluating and approving medicines. The ethical considerations surrounding gene editing, particularly germline editing, are a significant focus in European policy discussions. Many European countries have specific national laws that prohibit germline modification for reproductive purposes, reflecting a cautious approach to this transformative technology. International cooperation is essential to harmonize regulations and prevent ethical shopping or a patchwork of conflicting rules.
Public perception is another critical factor influencing the trajectory of CRISPR technology. Initial awe at its potential is often tempered by public apprehension regarding its safety and ethical implications. Misinformation and sensationalized media portrayals can further shape public opinion. Open communication, transparent research practices, and robust public engagement initiatives are vital for building trust and ensuring that societal values are integrated into the development and deployment of gene-editing technologies. Educational campaigns that explain the science in accessible terms, highlight the benefits for treating diseases, and address ethical concerns are crucial for fostering informed public discourse.
Global Regulatory Divergence
The global regulatory landscape for gene editing is characterized by significant divergence, creating both opportunities and challenges for researchers and developers. While countries like the United States and those in the European Union have established agencies to oversee gene therapies, the specific rules and guidelines can vary considerably. This can impact the speed at which treatments are developed, approved, and made available to patients.
For example, the United Kingdom has expressed a willingness to explore germline gene editing for therapeutic purposes under strict conditions, differentiating itself from some other European nations. China has also been at the forefront of gene editing research, with notable (and ethically controversial) applications in human embryos. These differing approaches highlight the need for ongoing international dialogue and collaboration to establish a consensus on ethical boundaries and safety standards, particularly for heritable genome modifications.
The World Health Organization (WHO) has been actively involved in fostering global discussions on the governance of human genome editing. It has established an expert advisory committee to provide recommendations on the ethical, legal, and social implications of human genome editing, aiming to guide national and international policy development. The goal is to ensure that gene editing technologies are used responsibly and for the benefit of all humanity, while mitigating potential risks.
Building Public Trust and Engagement
For CRISPR to reach its full therapeutic potential and be accepted by society, building and maintaining public trust is paramount. This involves transparent communication about research progress, potential risks, and ethical considerations. Scientists and policymakers must actively engage with the public, addressing concerns and fostering informed dialogue rather than making decisions in isolation.
Citizen juries, public consultations, and educational initiatives are important tools for fostering engagement. These platforms allow diverse voices to be heard and incorporated into the decision-making process. When the public feels informed and involved, they are more likely to support the responsible development and application of gene-editing technologies. The ethical quandaries surrounding CRISPR are not solely for scientists to resolve; they are societal issues that require a broad and inclusive conversation.
The "CRISPR babies" incident in China in 2018, where a scientist claimed to have created the world's first gene-edited babies, served as a stark reminder of the importance of ethical oversight and public transparency. The global outcry highlighted the urgent need for robust international guidelines and a shared understanding of responsible innovation. Such events underscore the responsibility of the scientific community and regulatory bodies to act with utmost diligence and engage proactively with the public to build confidence and prevent misuse.
The Future of Gene Editing: Beyond Human Health
While the focus on human health applications is understandable, CRISPR's potential extends far beyond treating diseases in people. Its ability to precisely manipulate genetic material opens up a world of possibilities in agriculture, environmental science, and fundamental biological research. These applications, while less ethically charged than human germline editing, still warrant careful consideration and responsible development.
In agriculture, CRISPR is being used to develop crops that are more resilient to pests, diseases, and climate change. It can enhance nutritional content, increase yields, and reduce the need for chemical pesticides and herbicides. For example, researchers are developing drought-resistant wheat varieties and disease-resistant rice. These advancements could play a crucial role in global food security and sustainable agriculture. However, concerns about genetically modified organisms (GMOs) persist, and public acceptance will be key to the widespread adoption of CRISPR-edited crops.
Environmental applications are also being explored. CRISPR could be used to develop organisms capable of cleaning up pollution, such as oil spills or plastic waste. It could also aid in conservation efforts by helping to restore endangered species or combat invasive ones. For instance, gene drives, a powerful application of CRISPR, could be engineered to spread a specific genetic trait through a wild population, potentially controlling disease-carrying mosquitoes or eradicating invasive rodents. However, the release of genetically modified organisms into the environment raises complex ecological questions and requires extensive risk assessment.
Fundamental biological research continues to be a major beneficiary of CRISPR. Its precision and ease of use have revolutionized the way scientists study gene function, develop disease models, and explore complex biological pathways. Understanding the intricate workings of DNA and cellular processes is a prerequisite for developing new therapies and technologies. CRISPR has become an indispensable tool in laboratories worldwide, accelerating the pace of discovery across a vast spectrum of biological disciplines.
Revolutionizing Agriculture and Food Security
CRISPR technology holds immense promise for transforming agriculture and addressing the growing challenges of feeding a global population. By enabling precise genetic modifications, it offers a way to improve crop yields, enhance nutritional value, and increase resistance to environmental stressors and diseases, all without necessarily introducing foreign DNA from different species, a hallmark of traditional GMOs. This distinction can be crucial for public acceptance and regulatory pathways in some regions.
For instance, researchers are using CRISPR to develop crops that are more efficient in their use of water and nutrients, which is particularly important in regions facing water scarcity and soil degradation. Disease resistance can be enhanced, reducing the reliance on chemical pesticides and fungicides, thereby contributing to more sustainable farming practices. Furthermore, CRISPR can be employed to boost the levels of essential vitamins and minerals in staple crops, combating malnutrition in vulnerable populations. For example, Golden Rice, engineered to produce beta-carotene, is one such example, though its development has been slow due to regulatory hurdles and public perception.
The development of allergen-free or hypoallergenic versions of common foods is another exciting prospect. By precisely editing genes responsible for producing allergenic proteins, CRISPR could make foods like peanuts or wheat safer for individuals with severe allergies. This could significantly improve the quality of life for millions of people worldwide and reduce the burden on healthcare systems. The speed and precision of CRISPR editing are key advantages, allowing for faster development cycles compared to traditional breeding methods.
Environmental Applications and Conservation
The power of CRISPR to alter genetic makeup extends to environmental applications, offering innovative solutions to pressing ecological challenges. One of the most talked-about applications is the development of gene drives, which can force a particular gene to spread rapidly through a wild population. This technology has the potential to combat diseases like malaria by making mosquitoes unable to transmit the parasite, or to control invasive species that threaten native ecosystems, such as rodents on islands.
However, the potential ecological impact of releasing gene-drive organisms into the wild is a subject of intense scientific and ethical debate. The unintended consequences of altering entire species or ecosystems are a major concern. International agreements and rigorous biosafety assessments are crucial before any such applications are deployed. The precautionary principle is often invoked, emphasizing the need for caution when dealing with interventions that could have irreversible effects on natural systems. Scientists are developing safeguards, such as 'underdrive' systems or 'reversal drives,' to mitigate these risks and ensure that gene drives can be controlled or reversed if necessary.
Beyond gene drives, CRISPR can be used for a variety of other environmental purposes. For example, it could be employed to engineer microbes that are more effective at breaking down plastic waste or remediating polluted sites. It might also be used to enhance the resilience of coral reefs to ocean acidification and warming, or to develop trees that are resistant to devastating diseases like the emerald ash borer. These applications highlight CRISPR's potential as a powerful tool for ecological restoration and stewardship.
Conclusion: A Measured Approach to a Transformative Technology
CRISPR technology stands at a pivotal moment, poised to redefine medicine and biotechnology. Its capacity to precisely edit DNA offers unprecedented opportunities to cure genetic diseases, develop more resilient crops, and address pressing environmental challenges. The scientific progress has been breathtaking, moving from theoretical concept to tangible therapeutic interventions in a remarkably short period. The potential benefits are immense, promising a future where previously incurable diseases become treatable, and where we have more sophisticated tools to manage our planet's health.
However, this transformative power is accompanied by significant ethical quandaries and safety considerations. The debates surrounding germline editing, equitable access, and the potential for enhancement applications are not merely academic exercises; they are essential dialogues that must guide the responsible development and deployment of CRISPR. The scientific community, policymakers, ethicists, and the public must collaborate to establish clear ethical guidelines and robust regulatory frameworks that ensure this technology is used for the benefit of all humanity, while minimizing risks and unintended consequences.
As CRISPR technology continues to evolve, a measured and thoughtful approach is paramount. We must foster innovation while upholding ethical principles, ensuring that scientific advancement is aligned with societal values. The path forward requires ongoing research, open dialogue, international cooperation, and a commitment to transparency. By navigating these complex challenges with wisdom and foresight, we can harness the full potential of CRISPR to create a healthier, more sustainable, and equitable future.
Reuters: CRISPR gene-editing therapy heads for human trials
Nature: Gene editing: the CRISPR revolution